Express Healthcare
Home  »  News  »  India has the world’s second largest population with inflammatory bowel disease: Wellness 365

India has the world’s second largest population with inflammatory bowel disease: Wellness 365

0 489
Read Article

The platform launched a month-long campaign #ManageYourIBD, in association with Indian gastroenterologists from the key metro cities

Wellness 365, a community representing Indian medical professionals and practitioners, announced that India today has an estimated 1.5 million patients affected by the Inflammatory Bowel Disease (IBD), putting the country second only to the US with 1.6 million patients. Also, these numbers are rising at a high single digit rate, as Indians have a greater than average risk of getting this disease.

To educate people and help them receive appropriate medical intervention, the platform launched a month-long campaign #ManageYourIBD, in association with Indian gastroenterologists from the key metro cities. The campaign was launched in support of the World IBD Day. This will complement the global movement with hashtag #MakeIBDwork.

Inflammatory Bowel Disease is an intestinal disorder which involves prolonged inflammation of the digestive tract and if left untreated can lead to irreversible damage of the intestines involving conditions like intestinal obstruction, intestinal perforation, and a higher risk of colorectal cancer. IBD is not cured by regular medication and requires the involvement of a specialist often requiring long-term management. Broadly there are two types of IBD’s – Ulcerative Colitis (UC) and Crohn’s Disease (CD).

Explaining the symptoms, Dr Rudrajit Sinha, Gastro-Intestinal Surgeon, Advanced Laparoscopy & Robotics, The Calcutta Medical Research Institute, Kolkata, says, “An IBD patient suffers from persistent abdominal cramps with irregular bowel habits and occasional passage of mucus and blood in stools. The disease is often associated with unexpected weight loss and the patient is resistant to usual treatments for stomach ailments.”

The diagnosis for IBD’s can be challenging, explains Dr Ajay Choksi, Consultant and Head, Dept. of Gastroenterology, Nanavati Hospital, Mumbai, “Many self-limited illnesses like bacterial infections and protozoal illnesses can mimic IBD on gross endoscopic and histologic findings but do not last beyond a month. Very often it may be impossible to differentiate between tuberculosis and Crohn’s disease which is when therapeutic trials and follow ups may be required for a precise diagnosis. Timely and early diagnosis increases the probability of inducing easy and durable remission of the disease. Vast majority of the patients can be successfully managed with medications.”

Elaborating on the risks and the available treatment options, Dr Ajay Bhalla, Director & Head Gastroenterology, Fortis Hospital, Noida, says “Medical management remains the key modality in the treatment of inflammatory bowel diseases. In case of ulcerative colitis, the need for surgical intervention is low at about 6 per cent for Indian patients while the worldwide average being about 10-12 per cent. Medical management with drugs like 5-ASAs, steroids and azathioprines and use of biologics gives effective outcomes.”

“However, in case of Crohn’s disease, the patient can end up with conditions like intestinalcrystallization or recurrent obstruction, where surgery may be required. It is seen worldwide and in India too that about one third of patients with Crohn’s disease require surgery at some point of time. Rest of the patients are successfully managed with medical management through drugs like steroids andazathioprines and now the use of biologics which would change the whole course of treatment. As the use of biologics becomes more common in India, I guess the requirement of surgery will go down further,” he added.

Delving into the impact of the disease, if it is left untreated, Dr Amarender Puri, Vice Chairman, Institute of Digestive and Hepatobiliary Sciences, Medanta, Gurugram, “There is a definite risk of colorectal cancer if IBD is left untreated. The risk is in direct proportion to the duration of the disease. It is negligible during the first 8-10 years but steadily increases thereafter. Currently the risk is thought to be about 10 per cent among those with the disease for 25-30 years. This risk is particularly much more among patients who have been irregular with their treatment vis a vis those who are fully compliant. Additionally, untreated disease leads to long-standing anaemia and protein loss from the body.”

Interestingly, factors like the socioeconomic and demographic classification play a role in the incidence of the disease, explains Dr Piyush Ranjan, Sr Consultant, Institute of Liver Gastroenterology & Pancreatico Biliary Sciences, Sir Ganga Ram Hospital, Delhi, “In general, IBD is more common among urban population and the higher socioeconomic groups. Both males and females have an equal chance of having ulcerative colitis. However, in case of Crohn’s disease, females have a slightly higher preponderance.”

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More